Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 157892
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 115
  • list Pharmaceuticals and Healthcare

Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear after several months of treatment with chemotherapeutic agents, gemcitabine and fluorouracil being the most common drugs causing reaction. Chemotherapy induced acryl erythema is a dose dependent condition, regression of which can be achieved by discontinuation of chemotherapy or by dose reduction. Treatment for chemotherapy induced acryl erythema includes symptomatic treatment with analgesics and antihistaminic drugs to reduce pain and edema.

Scope of the Report:

This report studies the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market by product type and applications/end industries.

Surge in usage of chemotherapeutic agents due to increasing incidence of cancers is the major growth driver of global chemotherapy induced acral erythema treatment market.Moreover, lifestyle up-gradation, increasing number of smokers are some secondary considerations accountable for rise in global chemotherapy induced acral erythema treatment market.

The global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Taro

Oceanside Pharmaceuticals

Pfizer

Novartis

A-S Medication Solutions

Preferred Pharmaceuticals

Syntex Pharmaceuticals

Valeant Canada

Technilab Pharma

Allergan

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Analgesics

Anti-Inflammatory And Anti-Edematous Agents

Antihistaminic

NSAIDs

Oral/Topical Glucocorticoids

Pyridoxine (Vitamin B6)

Others

Market Segment by Applications, can be divided into

Pharmacy And Drugstores

Hospital Pharmacy

Online Drug Stores

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Overview

1.1 Product Overview and Scope of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment

1.2 Classification of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment by Types

1.2.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Comparison by Types (2017-2023)

1.2.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share by Types in 2017

1.2.3 Analgesics

1.2.4 Anti-Inflammatory And Anti-Edematous Agents

1.2.5 Antihistaminic

1.2.6 NSAIDs

1.2.7 Oral/Topical Glucocorticoids

1.2.8 Pyridoxine (Vitamin B6)

1.2.9 Others

1.3 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market by Application

1.3.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Pharmacy And Drugstores

1.3.3 Hospital Pharmacy

1.3.4 Online Drug Stores

1.4 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market by Regions

1.4.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Status and Prospect (2013-2023)

1.5 Global Market Size of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment (2013-2023)

2 Manufacturers Profiles

2.1 Taro

2.1.1 Business Overview

2.1.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.2 Oceanside Pharmaceuticals

2.2.1 Business Overview

2.2.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.3 Pfizer

2.3.1 Business Overview

2.3.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.4 Novartis

2.4.1 Business Overview

2.4.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.5 A-S Medication Solutions

2.5.1 Business Overview

2.5.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.6 Preferred Pharmaceuticals

2.6.1 Business Overview

2.6.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.7 Syntex Pharmaceuticals

2.7.1 Business Overview

2.7.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.8 Valeant Canada

2.8.1 Business Overview

2.8.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.9 Technilab Pharma

2.9.1 Business Overview

2.9.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.10 Allergan

2.10.1 Business Overview

2.10.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, Gross Margin and Market Share (2016-2017)

3 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Competition, by Players

3.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players Market Share

3.2.2 Top 10 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players Market Share

3.3 Market Competition Trend

4 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Regions

4.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Market Share by Regions

4.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

4.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

4.5 South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

5 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries

5.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries (2013-2018)

5.2 USA Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

5.3 Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

5.4 Mexico Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

6 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries

6.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries (2013-2018)

6.2 Germany Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

6.3 UK Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

6.4 France Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

6.5 Russia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

6.6 Italy Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries

7.1 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries (2013-2018)

7.2 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

7.3 Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

7.4 Korea Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

7.5 India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

8 South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries

8.1 South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries (2013-2018)

8.2 Brazil Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

8.3 Argentina Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

8.4 Colombia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment by Countries

9.1 Middle East and Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Countries (2013-2018)

9.2 Saudi Arabia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

9.3 UAE Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

9.4 Egypt Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

9.5 Nigeria Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

9.6 South Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Growth Rate (2013-2018)

10 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Segment by Type

10.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue and Market Share by Type (2013-2018)

10.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Forecast by Type (2018-2023)

10.3 Analgesics Revenue Growth Rate (2013-2023)

10.4 Anti-Inflammatory And Anti-Edematous Agents Revenue Growth Rate (2013-2023)

10.5 Antihistaminic Revenue Growth Rate (2013-2023)

10.6 NSAIDs Revenue Growth Rate (2013-2023)

10.7 Oral/Topical Glucocorticoids Revenue Growth Rate (2013-2023)

10.8 Pyridoxine (Vitamin B6) Revenue Growth Rate (2013-2023)

10.9 Others Revenue Growth Rate (2013-2023)

11 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Segment by Application

11.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share by Application (2013-2018)

11.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Forecast by Application (2018-2023)

11.3 Pharmacy And Drugstores Revenue Growth (2013-2018)

11.4 Hospital Pharmacy Revenue Growth (2013-2018)

11.5 Online Drug Stores Revenue Growth (2013-2018)

12 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Forecast (2018-2023)

12.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Forecast (2018-2023)

12.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Forecast by Regions (2018-2023)

12.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Forecast (2018-2023)

12.4 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Forecast (2018-2023)

12.6 South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Picture

Table Product Specifications of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery